Milan, Italy / Copenhagen, Denmark – Amplifon, the world’s largest pure-play hearing aid retailer, has announced a definitive agreement to acquire GN Hearing from GN Store Nord in a landmark transaction valued at approximately €2.3 billion (US$2.64 billion) on a cash-free, debt-free basis. This strategic move, announced on March 16, 2026, is poised to fundamentally transform the global hearing care industry, creating a vertically integrated behemoth spanning product development, manufacturing, distribution, and patient care. The proposed acquisition, if completed, would combine Amplifon’s expansive retail footprint and clinical expertise with GN Hearing’s robust manufacturing capabilities and innovative technology portfolio, including prominent brands like ReSound, Jabra Enhance, and Beltone.
A Transformative Merger: Details of the Agreement
The agreement, which has received approval from the boards of both companies, outlines that GN Store Nord will receive €1.69 billion (US$1.94 billion) in cash and 56 million Amplifon shares upon closing. This structure will position GN Store Nord as a significant strategic shareholder in Amplifon, holding an approximate 16% stake on a pro-forma basis, assuming a planned equity raise. If no equity raise is completed, GN’s ownership at closing would be about 19.8%. The shares are expected to be subject to customary lock-up and transfer restrictions. The transaction is projected to close by the end of 2026, contingent upon crucial regulatory approvals and the successful carve-out of GN Hearing from the broader GN Group. This deal is set to become the largest straight acquisition in the history of the hearing industry, surpassing previous mergers in sheer transaction value.
Amplifon’s Strategic Rationale: Forging a Vertically Integrated Leader
For Amplifon, this acquisition represents a pivotal shift from its traditional role as a retailer that primarily dispensed devices from external suppliers. Historically, Amplifon, which operates under its namesake brand and through its prominent Miracle Ear network, has avoided direct manufacturing. By integrating GN Hearing, Amplifon gains direct control over a significant portion of its supply chain, fostering a seamless ecosystem from research and development to patient delivery.
Enrico Vita, CEO of Amplifon, underscored the monumental nature of the acquisition in a press statement. "Today marks a turning point for Amplifon," Vita declared. "We are announcing the most transformative acquisition in our 75-year-long history, that will fundamentally change the future of the hearing care industry worldwide and create significant and long-term value for all our stakeholders. With combined revenues of approximately €3.3 billion (US$3.79 billion), a presence in more than 100 countries, a cutting-edge R&D platform, leading manufacturing capabilities, and an unparalleled commercial network, we will be forming a truly global vertically integrated leader in audiology."
The company anticipates achieving substantial financial synergies, identifying between €60 million and €80 million (US$69 million – $92 million) in net EBITDA synergies by the end of 2029, with the majority expected to originate from volume insourcing. This vertical integration is designed to enhance efficiency, optimize product development, and broaden the range of advanced hearing solutions available to patients and hearing care professionals globally. Susan Carol Holland, Amplifon Chairperson, emphasized the long-term vision: "Today we celebrate the realization of a dream that strengthens our ambition: to integrate technology and innovation with our deep understanding of patients for the benefit of hearing care professionals and the people they serve with empathy and dedication. This milestone allows us to pursue even more effectively the mission with which my family founded Amplifon over 75 years ago, and has guided its growth ever since: to provide outstanding care to a growing number of people, helping them rediscover the full emotions of sound and live their lives to the fullest."
GN Store Nord’s Strategic Pivot: Focusing on Audio and Video Peripherals
From GN Store Nord’s perspective, the divestment of its hearing business marks a strategic reset designed to streamline its operations and focus on its core audio and video peripherals segment. This segment, which includes brands like Jabra, is seen as a high-growth area where GN can leverage its expertise in premium audio brands, sound-processing technologies, and low-power edge AI.
)
Peter Karlströmer, GN Group CEO, articulated the company’s vision for this strategic shift. "We are today acting on an opportunity to create a global leader in hearing care together with Amplifon. Together we are well positioned to develop into an industry leader, driving further innovation and benefits to our industry. For GN, this also creates an opportunity to strengthen our position in the large and attractive audio and video peripherals markets. We have unique brands, talents and capabilities, and a rich set of opportunities. This is very exciting for GN’s customers, investors, and employees working in Hearing and the rest of GN."
The proceeds from the sale, which GN expects to exceed its net interest-bearing debt, will enable the company to significantly reduce its leverage, invest further in its remaining businesses, and potentially return capital to shareholders. This move positions GN Store Nord to become a more agile and focused technology company, better equipped to capitalize on emerging trends in communication and sound technology. The sale involves approximately 5,500 employees worldwide from GN Hearing, its extensive portfolio of hearing brands (ReSound, Beltone, Interton, Danavox, Jabra Enhance, Danalogic), all related intellectual property, R&D, manufacturing facilities, and operations. Notably, GN’s current financial investment of approximately 19% in NationsBenefits LLC is not included in the deal.
Reshaping the Global Hearing Care Landscape: Implications for the Industry
The proposed acquisition is set to dramatically redraw the competitive map of the global hearing care industry, which has historically been dominated by a handful of major manufacturers often referred to as the "Big 5" (Sonova, Demant, WS Audiology, Starkey, and GN Hearing). Amplifon’s move to acquire one of these key manufacturers signals a new era of vertical integration and consolidation.
The combined entity will boast impressive scale: approximately €3.3 billion (US$3.79 billion) in combined annual revenue, a global presence in over 100 countries, more than 20,000 employees, over 700 R&D professionals, and an extensive patent portfolio exceeding 2,800 patents. This scale positions Amplifon as a formidable force, capable of driving innovation, influencing market trends, and potentially challenging the traditional power dynamics between manufacturers and retailers.
)
The hearing care market is experiencing sustained growth, driven by an aging global population, increased awareness of hearing health, and rapid technological advancements. This deal enables Amplifon to better capitalize on these secular growth trends by controlling both the product development and the point of patient interaction. The company intends to preserve GN Hearing’s distinct identity, brands, and core capabilities, aiming to leverage its engineering bases and manufacturing footprints in Denmark, China, Malaysia, and the United States for continued product innovation. For fiscal year 2025, GN Hearing reported robust revenues of DKK 7.2 billion (US$1.1 billion) and a pro forma, carved-out adjusted EBITDA of approximately €220 million (US$252.5 million), with nearly half of its revenue (49%) originating from the Americas, 28% from Europe, and 23% from the rest of the world.
The transaction will also create a more balanced revenue mix for Amplifon, shifting towards a blend of retail and service revenue alongside technology and product revenue. This diversification is expected to contribute to improved revenue growth, profitability, and overall earnings for the new group. Based on 2025 results, the combined business is projected to generate pro-forma adjusted EBITDA of approximately €830 million (US$952.5 million), including expected run-rate synergies, with a healthy margin of roughly 25%.
Financial Outlook and Funding Strategy
To finance the cash portion of the acquisition, Amplifon will utilize a bridge loan, which it plans to refinance over time through a combination of debt and equity and/or equity-linked instruments. The company projects a pro-forma net debt to adjusted EBITDA ratio of about 3.0x at closing, excluding net synergies and assuming up to €0.75 billion (US$860 million) from a future equity raise. The new group is expected to deleverage over the subsequent 2 to 3 years through robust cash generation.
Obstacles and Regulatory Scrutiny
)
Despite the definitive agreement and mutual board approvals, the transaction faces several significant hurdles before its anticipated close by the end of 2026. The primary challenges include obtaining customary regulatory and antitrust approvals across various jurisdictions. Given the substantial market share of both Amplifon and GN Hearing in their respective segments, antitrust regulators will meticulously scrutinize the deal for potential impacts on competition, consumer choice, and pricing.
Another critical procedural step is the carve-out of GN Hearing from the broader GN Group, which GN has indicated will involve a statutory demerger under Danish company law. This process is inherently complex, requiring the separation of assets, liabilities, intellectual property, and operational functions, making it more intricate than a straightforward asset sale. One-time integration costs are estimated to total approximately €80 million over the first 2-3 years post-closing.
Furthermore, the shareholder base of GN Store Nord presents a unique dynamic. Demant, the parent company of Oticon and a major competitor in both manufacturing and retail (through HearingLife, Hidden Hearing, and KIND), is GN’s largest shareholder, holding roughly 12% of shares and votes. While GN’s board has approved the transaction, Demant’s dual role as a significant shareholder and an industry rival adds an interesting layer of complexity and observation as the deal progresses. The companies have also indicated that GN and Ampliter (Amplifon’s controlling shareholder) are expected to enter into a shareholders’ agreement, which would grant GN the right to nominate a representative to Amplifon’s board, further solidifying their strategic partnership.
A New Era for Hearing Care
The Amplifon-GN Hearing acquisition represents a watershed moment for the global hearing care industry. It signifies a profound shift towards greater vertical integration, potentially setting new standards for innovation, product development, and patient care. As the world grapples with an increasing prevalence of hearing loss and a growing demand for advanced solutions, the formation of this new, integrated leader promises to bring significant changes to how hearing aids are developed, distributed, and ultimately, how millions of people worldwide experience the gift of sound. The industry, consumers, and healthcare professionals will be watching closely as this transformative deal navigates its final stages towards completion.